Kaleido Biosciences Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

Dec 14

Recent updates

AMMINISTRATORE DELEGATO

Kaleido Biosciences non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Theodose Melas-Kyriazi	Independent Chairperson of the Board	5.3yrs	US$146.56k	Nessun dato
Laurie Glimcher	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
C. Kahn	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Jean Mixer	Independent Director	5.1yrs	US$127.23k	Nessun dato
Anthony Quinn	Independent Director	8.8yrs	US$124.73k	Nessun dato
Laura Kiessling	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Anne Prener	Independent Director	4.6yrs	US$118.73k	Nessun dato
Fergus Shanahan	Chairman of Scientific Advisory Board	5.2yrs	Nessun dato	Nessun dato
Max Nieuwdorp	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Peter Turnbaugh	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Robert Jenq	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di KLDO sono considerati esperti (durata media dell'incarico 5.8 anni).

Kaleido Biosciences Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Kaleido Biosciences, Inc. Announces Resignation of Katharine Knobil as Chief Medical Officer and Head of Research and Development, Effective as of January 29, 2021

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

Kaleido Biosciences, Inc. Announces Change of Role of Michael Bonney from Executive Chair of the Board to Chair of the Board

Kaleido Biosciences, Inc. Announces Management Changes, Effective October 13, 2020

Recent updates

Kaleido Biosciences, Inc. Announces Cessation of All of the Company’s Ongoing Operations

Kaleido Biosciences, Inc. announced delayed annual 10-K filing

Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease (COPD) Study

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.65 loss in 3Q 2020)

Price target increased to US$15.60

Price target decreased to US$14.33

Consensus forecasts updated

Consensus forecasts updated

Chairman of the Board Michael Bonney has left the company

Consensus forecasts updated

Price target increased to US$17.83

Consensus revenue estimates fall to US$547.0k

Kaleido Biosciences EPS misses by $0.01

Consultant has left the company

Revenue and earnings miss expectations

Is Kaleido Biosciences, Inc. (NASDAQ:KLDO) Popular Amongst Insiders?

Kaleido Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $60.375 million.

Kaleido Biosciences announces $50M proposed public offering

New 90-day high: US$14.21

Kaleido Biosciences, Inc. Announces Resignation of Katharine Knobil as Chief Medical Officer and Head of Research and Development, Effective as of January 29, 2021

Kaleido Biosciences, Inc. Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-To-Moderate COVID-19

Kaleido Bio's KB109 shows benefit in COVID-19 study

New 90-day high: US$11.40

Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19

Kaleido concludes enrollment in KB109 study in COVID-19

Price target raised to US$14.00

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

Analysts update estimates

Price target lowered to US$11.60

Earnings beat expectations

Analysts update estimates

Kaleido Biosciences, Inc. Announces Change of Role of Michael Bonney from Executive Chair of the Board to Chair of the Board

Kaleido Biosciences, Inc. Provides Update on KB109 Clinical Data Timeline

Kaleido Biosciences, Inc. Announces Management Changes, Effective October 13, 2020

Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis

New 90-day low: US$5.09

New 90-day low - US$5.78

New 90-day high - US$8.52

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media

Età media